Patrick Landazuri1, Jerry Shih2, Eric Leuthardt3, Sharona Ben-Haim4, Joseph Neimat5, Zulma Tovar-Spinoza6, Veronica Chiang7, Dennis Spencer7, David Sun8, Peter Fecci9, James Baumgartner10. 1. Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: plandazuri@kumc.edu. 2. Department of Neurosciences, University of California San Diego, San Diego, CA, USA. 3. Department of Neurosurgery, Washington University, St. Louis, MO, USA. 4. Department of Neurosurgery, University of California San Diego, San Diego, CA, USA. 5. Department of Neurosurgery, University of Louisville, Louisville, KY, USA. 6. Department of Neurosurgery, SUNY Upstate Medical University, Syracuse, NY, USA. 7. Yale University School of Medicine, Yale University, New Haven, CT, USA. 8. Norton Neuroscience Institute, Norton Health Care, Louisville, Kentucky, USA. 9. Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA. 10. Department of Neurosurgery, Florida Hospital Advent Health, Orlando, FL, USA.
Abstract
OBJECTIVE: To report one-year seizure outcomes, procedural data, and quality of life scores following laser interstitial thermal therapy (LITT) of epileptogenic foci. METHODS: Data from an ongoing prospective, multi-center registry were assessed. Procedural information, Engel seizure outcomes, and quality of life (QoL) scores were analyzed. A responder analysis was performed to better understand potential clinical characteristics that could influence seizure outcome. RESULTS: Sixty patients have been enrolled into LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System) specifically for epilepsy treatment, of which 42 reached one year follow up. Engel I outcome was achieved in 64.3 % at one year follow up. Patients with mesial temporal lobe epilepsy (MTLE) comprised 56.7 % of this cohort of multiple epilepsy types. Other significant etiologies included focal cortical dysplasia, hypothalamic hamartoma, cavernoma, heterotopias, and tuberous sclerosis. Median length of stay was 32.7 h. At discharge, head pain score averaged 1.4 ± 2.1 on a scale from 1 to 10. Five adverse events were reported, one categorized as serious. Seizure worry and social functioning scores improved significantly in quality of life measures. SIGNIFICANCE: Surgical treatment with LITT for epileptic foci is a safe and effective treatment option for people with drug resistant epilepsy. Our multicenter prospective seizure outcomes continue to expand published LITT experience in MTLE as well as non-MTLE epilepsies. The minimally invasive nature allows for short hospitalizations with minimal reported pain and discomfort.
OBJECTIVE: To report one-year seizure outcomes, procedural data, and quality of life scores following laser interstitial thermal therapy (LITT) of epileptogenic foci. METHODS: Data from an ongoing prospective, multi-center registry were assessed. Procedural information, Engel seizure outcomes, and quality of life (QoL) scores were analyzed. A responder analysis was performed to better understand potential clinical characteristics that could influence seizure outcome. RESULTS: Sixty patients have been enrolled into LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System) specifically for epilepsy treatment, of which 42 reached one year follow up. Engel I outcome was achieved in 64.3 % at one year follow up. Patients with mesial temporal lobe epilepsy (MTLE) comprised 56.7 % of this cohort of multiple epilepsy types. Other significant etiologies included focal cortical dysplasia, hypothalamic hamartoma, cavernoma, heterotopias, and tuberous sclerosis. Median length of stay was 32.7 h. At discharge, head pain score averaged 1.4 ± 2.1 on a scale from 1 to 10. Five adverse events were reported, one categorized as serious. Seizure worry and social functioning scores improved significantly in quality of life measures. SIGNIFICANCE: Surgical treatment with LITT for epileptic foci is a safe and effective treatment option for people with drug resistant epilepsy. Our multicenter prospective seizure outcomes continue to expand published LITT experience in MTLE as well as non-MTLE epilepsies. The minimally invasive nature allows for short hospitalizations with minimal reported pain and discomfort.
Authors: J Granna; E B Pitt; M E McKay; T J Ball; J S Neimat; D J Englot; R P Naftel; E J Barth; R J Webster Journal: Ann Biomed Eng Date: 2022-03-04 Impact factor: 3.934
Authors: Matthew M Grabowski; Ethan S Srinivasan; Eugene J Vaios; Eric W Sankey; Balint Otvos; Daria Krivosheya; Alex Scott; Michael Olufawo; Jun Ma; Elena I Fomchenko; James E Herndon; Albert H Kim; Veronica L Chiang; Clark C Chen; Eric C Leuthardt; Gene H Barnett; John P Kirkpatrick; Alireza M Mohammadi; Peter E Fecci Journal: Neurooncol Adv Date: 2022-06-02
Authors: James Sun; Katrina Barth; Shaoyu Qiao; Chia-Han Chiang; Charles Wang; Shervin Rahimpour; Michael Trumpis; Suseendrakumar Duraivel; Agrita Dubey; Katie E Wingel; Iakov Rachinskiy; Alex E Voinas; Breonna Ferrentino; Derek G Southwell; Michael M Haglund; Allan H Friedman; Shivanand P Lad; Werner K Doyle; Florian Solzbacher; Gregory Cogan; Saurabh R Sinha; Sasha Devore; Orrin Devinsky; Daniel Friedman; Bijan Pesaran; Jonathan Viventi Journal: Brain Commun Date: 2022-05-27
Authors: John F de Groot; Albert H Kim; Sujit Prabhu; Ganesh Rao; Adrian W Laxton; Peter E Fecci; Barbara J O'Brien; Andrew Sloan; Veronica Chiang; Stephen B Tatter; Alireza M Mohammadi; Dimitris G Placantonakis; Roy E Strowd; Clark Chen; Constantinos Hadjipanayis; Mustafa Khasraw; David Sun; David Piccioni; Kaylyn D Sinicrope; Jian L Campian; Sylvia C Kurz; Brian Williams; Kris Smith; Zulma Tovar-Spinoza; Eric C Leuthardt Journal: Neurooncol Adv Date: 2022-04-06